PMC full text:
Published online 2012 Jul 17. doi: 10.1093/infdis/jis470
Table 2.
Pharmacokinetics of R1479 on Study Day 1
| Parameter | Tmax, ha | Cmax, μMb | Cmin, μMb | Tlast, hc | AUClast, h × μM |
|---|---|---|---|---|---|
| Cohort 1 (1500 mg twice daily) | |||||
| Minimum | 2 | 5.46 | 2.71 | 12 | 42.63 |
| Median | 4 | 16.54 | 3.56 | 12 | 110.56 |
| Maximum | 8 | 19.76 | 4.93 | 12 | 130.70 |
| CV, % | 49.1 | 30.5 | 21.3 | … | 55.81 |
| Cohort 2 (3000 mg twice daily) | |||||
| Minimum | 2 | 8.78 | 2.14 | 12 | 70.05 |
| Median | 4 | 23.86 | 5.82 | 12 | 167.04 |
| Maximum | 12 | 90.60 | 15.73 | 12 | 608.09 |
| CV, % | 55.3 | 60 | 45.5 | … | 116.89 |
Abbreviations: AUClast, area under the log-transformed viremia curve; Cmax, maximum plasma concentration of R1479 on day 1; Cmin, minimum plasma concentration of R1479 on day 1; CV, coefficient of variation Tlast, time since treatment when the last sample for pharmacokinetic measurement was collected; Tmax, time after treatment when the maximum plasma concentration of R1479 was reached.